Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) Research & Development (2018 - 2025)

TransMedics (TMDX) has 8 years of Research & Development data on record, last reported at $20.7 million in Q4 2025.

  • For Q4 2025, Research & Development rose 25.73% year-over-year to $20.7 million; the TTM value through Dec 2025 reached $69.1 million, up 23.38%, while the annual FY2025 figure was $69.1 million, 23.38% up from the prior year.
  • Research & Development reached $20.7 million in Q4 2025 per TMDX's latest filing, up from $15.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $20.7 million in Q4 2025 and bottomed at $4.5 million in Q1 2021.
  • Average Research & Development over 5 years is $10.5 million, with a median of $9.5 million recorded in 2023.
  • Peak YoY movement for Research & Development: dropped 27.2% in 2021, then skyrocketed 93.83% in 2024.
  • A 5-year view of Research & Development shows it stood at $6.3 million in 2021, then dropped by 8.84% to $5.8 million in 2022, then soared by 86.95% to $10.8 million in 2023, then skyrocketed by 53.0% to $16.5 million in 2024, then rose by 25.73% to $20.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $20.7 million in Q4 2025, $15.3 million in Q3 2025, and $15.9 million in Q2 2025.